Background {#Sec1}
==========

Platelet (PLT) transfusion is used therapeutically in patients who are bleeding \[[@CR1]\], and is also recommended by guidelines \[[@CR2]\] to reduce the risk of bleeding in patients with thrombocytopenia (prophylactic transfusion). However, the benefit of prophylactic PLT administration in non-bleeding critically ill patients with thrombocytopenia has been questioned \[[@CR3], [@CR4]\]. This is important, as there is some evidence suggesting that PLT administration is associated with adverse effects including infection and sepsis \[[@CR5], [@CR6]\]. The association between blood component administration and hospital-acquired infection has been reported mainly for red blood cells (RBC) \[[@CR7]--[@CR9]\]. Nonetheless, this association is probably not restricted to RBC, as fresh frozen plasma (FFP) and PLT transfusion can also cause post transfusion immunomodulation \[[@CR10]\].

Platelets play a key role in the inflammatory and immune response, \[[@CR11]\] and some authors have hypothesised that PLT transfusion may lead to immunomodulation \[[@CR10], [@CR12]\]. Nonetheless, there has been no large study of PLT transfusion in ICU patients to investigate whether PLT administration is associated with an increased risk of developing hospital-acquired infection. Patients admitted to an ICU are likely to be particularly prone to transfusion-mediated immunomodulation \[[@CR13]\]. Therefore, we aimed to describe PLT transfusion in a large cohort of critically ill patients and to determine whether PLT transfusion is associated with hospital-acquired infection.

Methods {#Sec2}
=======

Patients and study design {#Sec3}
-------------------------

This is a retrospective study conducted in the mixed medical-surgical ICUs of two teaching hospitals in Melbourne (Australia). All patients admitted to one of these ICUs between July 2008 and September 2013 were included in the study. The Alfred Hospital (affiliated to Monash University), with a 45-bed ICU capacity, is a tertiary hospital and state-wide referral centre for trauma and heart and lung transplantation; the Austin Hospital (affiliated to the University of Melbourne), with a 20-bed ICU capacity, is a tertiary hospital and referral centre for liver transplantation for the states of Victoria, Tasmania and South Australia. The Research Ethics Committees of both institutions approved the study (LNR13/Austin/233 and Alfred 58/11).

Clinical data {#Sec4}
-------------

Clinical data were those prospectively extracted from local ICU databases used to collect and submit data to the Australian New Zealand Intensive Care Society (ANZICS) Adult Patient Database (APD). Data were collected on gender, date of birth, comorbidities, ICU and hospital admission and discharge dates, Acute Physiology And Chronic Health Evaluation (APACHE III) score at admission, ICU admission categories, requirement for and dates of initiation and cessation of mechanical ventilation (MV) or renal replacement therapy (RRT), and patient vital status at ICU and hospital discharge.

Transfusion data {#Sec5}
----------------

Data on all blood components issued and transfused to patients were retrieved from the blood bank laboratory information systems of each hospital. For each PLT unit administered, we recorded the date of transfusion, the type of product (apheresis or pooled), the volume, and the ABO and Rhesus D blood group. Administration of RBC, FFP and cryoprecipitate (CRYO) were also collected. Universal pre-storage leukodepletion was introduced in Australia prior to the study period, and therefore all blood products were pre-storage leukodepleted. Systematic screening of PLT for bacterial contamination was implemented at the same time by the Australian Red Cross Blood Service. PLT transfusion practices in critically ill patients were according to clinician discretion.

The national guidelines in place at the time of the study were the Australian Society of Blood Transfusion (ASBT) guidelines, which recommended prophylactic PLT transfusion at a threshold of 10 to 20 × 10^9^/L in bone marrow failure and a threshold of 50 × 10^9^/L prior to surgery or invasive procedures, \[[@CR14]\] and therapeutic PLT transfusion in bleeding patients in whom thrombocytopenia was considered a major contributor factor, when the platelet count was less than 50 × 109/L in the context of massive haemorrhage, or less than 100 × 10^9^/L in the presence of diffuse microvascular bleeding \[[@CR14]\]. An observational study conducted in Australia and New Zealand confirmed the compliance with these guidelines in ICU patients during the same study period with only 5% of PLT transfusions that were inappropriate \[[@CR15]\]. The updated guidelines published towards the end of the study period specifically for critical care included similar proposed thresholds for prophylactic PLT transfusion in the absence of bleeding (\<20 × 10^9^/L) and prior to invasive procedures (\<50 × 10^9^/L) \[[@CR16]\].

Microbiological data {#Sec6}
--------------------

Microbiological data were retrieved from the microbiology laboratory records (KESTRAL system, [www.kestral.com.au](http://www.kestral.com.au/), Melbourne, Victoria, Australia) at the Austin hospital, and from a prospectively maintained database by the infectious disease department at the Alfred hospital. Microbiological data included positive blood culture and positive urine culture (defined by the presence of no more than two bacterial or Candida pathogens, and at 10^5^ colony forming units (cfu)/mL or higher \[[@CR17]\]). Sample date and pathogens isolated were recorded. When a pathogen known to be a frequent contaminant of microbiological cultures (i.e. coagulase-negative staphylococcus) was isolated, only cases with two or more positive blood cultures with the same pathogen were considered as bloodstream infection.

Statistical analysis {#Sec7}
--------------------

Descriptive statistics are reported as mean (standard deviation) or median (interquartile range) according to data distribution. Hypothesis testing was performed using the chi-square test for categorical variables, Student *t* test for normally distributed data and Wilcoxon rank-sum test for non-normally distributed data. The relationship between PLT transfusion and ICU-acquired infection was determined by logistic regression with results reported using odds ratios (ORs) (95% confidence interval (CI)). Model discrimination and calibration were determined using the area under the receiver operating characteristic (ROC) curve and the Hosmer-Lemeshow statistic.

Infection was defined as either bacteraemia or bacteriuria occurring in the ICU after 48 hours of ICU stay. Multivariate analysis was performed adjusting for gender, APACHE III score, site, diagnosis category, year, whether the patient received invasive MV or RRT, and whether another type of transfusion (RBC, CRYO, or FFP) had been given prior to the first dose of PLT. Additional sensitivity analysis was performed, adjusting for each patient's propensity to receive a PLT transfusion; the propensity variable was calculated by using the predicted values of a multiple logistic regression model of platelet transfusion from pre-admission variables including comorbidity variables and the same variables as the multivariate analysis. Cox proportional hazards regression analysis was then performed, with the outcome of time of first infection, and including transfusion variables as time-varying covariates, and gender, APACHE III score, site, diagnosis category, year, and requirement for RRT and MV. Finally, three additional models were then also performed, considering only bacteraemia or bacteriuria as the infectious outcome and considering the number of platelet units transfused as a continuous variable. Propensity assumptions were determined using Schoenfeld residuals. To increase the robustness of our findings, a two-sided *p* value of 0.01 was considered to indicate significance. Statistical analysis was performed using STATA version 12.1 (StataCorp, TX, USA).

Results {#Sec8}
=======

Patient characteristics {#Sec9}
-----------------------

A total of 19,101 patients had at least one admission to of the either ICUs over the five and half year study period. Of these, 136 (0.7%) were excluded because of missing data, leaving 18,965 included in the present study. Of the 18,965 patients, 2250 (11.9%) received PLT in the ICU.

Patients' characteristics and comparisons between patients who received PLT in the ICU and those who did not are displayed in Table [1](#Tab1){ref-type="table"}. Patients who received PLT were younger (59 ± 17 vs 60 ± 17, *p* = 0.036) and more often male (67.2% vs 63.3%, *p* \< 0.01) than those who did not receive PLT. They had greater illness severity at ICU admission, with an APACHE III score of 65 ± 29 vs 52 ± 25 (*p* \< 0.01) and they more often had comorbidities (31% vs 19%, *p* \< 0.01). Patients who received PLT in the ICU were more often admitted with cardiovascular disease, gastrointestinal (GI) disease, trauma, or haematological disease than those who did not receive PLT. The majority of patients receiving PLT required invasive MV (87% vs 57%, *p* \< 0.01) and one fifth had RRT while in the ICU (20% vs 4%, *p* \< 0.01).Table 1Characteristics of patients with and without platelet (PLT) transfusion in the ICUVariablesAll patients *N* = 18,965Patients with PLT transfusion *N* = 2250Patients without PLT transfusion *N* = 16,715*P* valueAge, years, mean (SD)60 (18)59 (17)60 (17)0.04Gender, male, *n* (%)12 086 (63.7%)1 511 (67.2%)10 575 (63.3%)\<0.01APACHE III score, mean (SD)54 (26)65 (29)52 (25)\<0.01*Comorbidities* Any known comorbidity3 838 (20%)702 (31%)3 136 (19%)\<0.01 Cancer^a^857 (4.5%)192 (8.5%)665 (4.0%)\<0.01 Hepatic disease^b^674 (3.6%)216 (9.6%)458 (2.7%)\<0.01 Immunocompromised^c^1 180 (6.2%)311 (13.8%)869 (5.2%)\<0.01 IDDM511 (2.7%)60 (2.7%)451 (2.7%)0.93 Chronic respiratory disease840 (4.4%)92 (4.1%)748 (4.5%)0.40 CVD754 (4%)137 (6.1%)617 (3.7%)\<0.01 Chronic renal failure422 (2%)59 (2.6%)363 (2.2%)0.17Admission diagnosis Cardiovascular5 161 (27%)701 (31%)4 460 (27%)\<0.01 Gastrointestinal3 595 (19%)581 (26%)3 014 (18%)\<0.01 Haematological152 (0.8%)96 (4.3%)56 (0.3%)\<0.01 Neurological1 586 (8.4%)108 (4.8%)1 478 (8.8%)\<0.01 Renal/genitourinary1 017 (5.4%)108 (4.8%)909 (5.4%)0.2 Respiratory1 467 (7.7%)127 (5.6%)1 340 (8%)\<0.01 Sepsis503 (2.7%)73 (3.2%)430 (2.6%)0.06 Other^d^2 815 (14.8%)82 (3.6%)2 733 (16.4%)\<0.01 Trauma2 669 (14.1%)374 (16.6%)2 295 (13.7%)\<0.01Requirement for MV11 531 (61%)1 952 (87%)9 579 (57%)\<0.01Requirement for RRT1 135 (6%)449 (20%)686 (4%)\<0.01^a^Cancer group includes myeloma, lymphoma, leukaemia and metastases. ^b^Hepatic disease group includes liver cirrhosis, chronic liver disease and hepatic failure. ^c^Immunocompromised includes those listed as immunosuppressed or with immune disease. ^d^Other includes undefined, metabolic, muscle and skin, gynaecologic diseases. *PLT* platelets, *ICU* intensive care unit, *MV* mechanical ventilation, *RRT* replacement renal therapy, *APACHE* Acute Physiology And Chronic Health Evaluation, *IDDM* insulin-dependent diabetes mellitus, *CVD* chronic vascular diseases, *SD* standard deviations. *P* values comparing PLT transfusion group to the no-PLT transfusion group

### Transfusion characteristics {#Sec10}

PLT units (n = 6012) were transfused over the study period, with a median of 1 PLT unit (IQR 1--3) per patient. Patients with haematology admission diagnosis received more PLTs than the other critically ill patients. The ABO group of the PLT unit transfused was known in 2685 units and was mostly groups O (56%) and A (40%). PLT transfusions were Rhesus-D-positive in 71% of patients. Patients transfused with PLT were also transfused with RBC, FFP and CRYO in 79%, 62% and 33% of cases, respectively. These figures were significantly higher (*p* \< 0.01) than in patients without PLT transfusion (RBC 21%, FFP 6%, cryoprecipitate 0.8%). The first PLT transfusion occurred in the first 24 hours after ICU admission in 82.6% of patients.

### PLT transfusion and infections {#Sec11}

Overall, 411 patients (2.2%) experienced an ICU-acquired infection in ICU that was either bacteraemia or bacteriuria (Table [2](#Tab2){ref-type="table"}). A much higher proportion of patients who had received platelets developed infection (7.7%) compared to those who had not (1.4%) (*p* \< 0.01). PLT transfusion was associated with occurrence of both bacteraemia and bacteriuria (Table [2](#Tab2){ref-type="table"}). Patterns of pathogens isolated in blood culture and urine culture are displayed in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}.Table 2Platelet exposure and outcomesVariablesAll patients *N* = 18,965Patients with PLT transfusion *N* = 2250Patients without PLT transfusion *N* = 16,715*P* value\*Infections, *n* (%)  Any (blood or urine culture)  Blood culture  Urine culture411 (2.2) 178 (0.9) 262 (1.4)173 (7.7) 99 (4.4) 89 (4)238 (1.4) 79 (0.5) 173 (1)\<0.01 \< 0.01 \< 0.01Time to infection, days median (IQR)  Any (blood or urine)  Blood culture  Urine culture7.1 (4.2--12) 7.9 (4.5--12) 6.8 (4.1--11.7)8.9 (5.1--15.0) 8.4 (5--14) 9.1 (5.2--17)6.4 (3.9--10) 6.6 (4.3--12) 6.3 (3.8--10.1)\<0.01 \< 0.01 0.25*PLT* platelets, *IQR* interquartile range. **\*** *P* values comparing PLT transfusion group to the no-PLT transfusion group Table 3Microbiological features of positive urine cultures occurring in patients with and without PLT transfusion in the intensive care unitPathogensPatients with positive UC *N* = 292Patients with positive UC and with PLT transfusion *N* = 99Patients with positive UC without PLT transfusion *N* = 193*P* valueEnterobactericeae *Enterococcus*17 (5.8%)43 (43.4%)108 (56%)0.04*Staphylococcus* sp.38 (19.5%)2 (2%)15 (7.8%)0.04*Candida* sp.7 (2.4%)3 (3%)4 (2.1%)0.44Non-fermentive GNB90 (30.8%)44 (44.4%)46 (23.8%)\< 0.01Other30 (10.3%)9 (9.1%)21 (10.9%)0.632 (0.7%)1 (1%)1 (0.5%)0.56UC with \>1 microorganism25 (8.6%)5 (5.1%)20 (10.4%)0.12*PLT* platelets, *GNB* Gram-negative Bacilli; *UC* urine culture. *P* values comparing PLT transfusion group to the no-PLT transfusion group Table 4Microbiological features of positive blood cultures in patients with and without PLT transfusionPathogensPatients with positive blood culture *N* = 195Patients with positive blood culture who had PLT transfusion *N* = 108Patients with positive blood culture without PLT transfusion *N* = 87*P* valueEnterobactericeae54 (27.7%)28 (26%)26 (29%)0.54*Enterococcus*38 (19.5%)27 (25%)11 (13%)0.03*Staphylococcus aureus*20 (10.3%)9 (8.3%)11 (12.6%)\<0.01CNS39 (20%)21 (19.4%)18 (20.7%)0.83Candida36 (18.5%)26 (24.1%)10 (11.5%)0.02Non-fermentive GNB16 (8.2%)7 (6.5%)9 (10.3%)0.33Other2 (1%)1 (0.9%)1 (1.2%)0.88BC with \>1 microorganism14 (7.2%)9 (8.3%)5 (5.8%)0.49*PLT* Platelets, *CNS* coagulase negative Staphylococcus, *GNB* Gram-negative Bacilli, *BC* blood culture. *P* values comparing PLT transfusion group to the no-PLT transfusion group

After adjusting for confounders (gender, APACHE III score, site, diagnosis category, year, whether another type of transfusion had been given prior to the PLT transfusion, MV and/or RRT requirement), PLT transfusion was associated with an increased risk of infection (adjusted odds ratio (OR) 2.56, 95% confidence interval (CI) 1.98--3.31, *p* \< 0.01). The other independent risk factors for infection were female gender, patient severity at admission, requirement for invasive MV, requirement for RRT, admission diagnosis, administration of RBC prior to PLT transfusion and year (Table [5](#Tab5){ref-type="table"}). As there were no significant interactions between PLT transfusion and other variables in the model, there was no evidence to suggest that the relationship between PLT transfusion and infection differed according to any of the covariates considered, including diagnosis category. When adjusting for the propensity to receive platelet transfusion, PLT transfusion remained associated with an increased risk of infection ([Appendix](#Sec17){ref-type="sec"}).Table 5Independent risk factors for infection in a multivariate analysisVariables^a^Adjusted odds ratio\*95% Confidence interval*P* valuePLT2.561.98-3.31\<0.01Gender, male0.400.33-0.50\<0.01APACHE III score1.011.00-1.01\<0.01RBC transfusion^b^1.501.19-1.90\<0.01FFP transfusion^b^0.920.68-1.240.57Cryoprecipitate^b^1.140.75-1.730.53Invasive mechanical ventilation3.162.29-4.36\<0.01RRT4.753.56-6.32\<0.01^a^Other confounders include centre, year and admission diagnosis. ^b^Only blood products transfused prior to platelets (PLT) transfusion are considered in the analysis. *RBC* red blood cells, *FFP* fresh frozen plasma, *RRT* renal replacement therapy, *APACHE III* Acute Physiology And Chronic Health Evaluation III. \*Hosmer-Lemeshow *p* value \>0.54, area under the receiver operating characteristic curve 0.83

When considering blood product transfusion (PLT, RBC, FFP or CRYO) as time-varying covariates, PLT administration remained associated with infection (adjusted HR 1.85, 95% CI 1.41--2.41, *p* \< 0.01) (Table [6](#Tab6){ref-type="table"}). When considering bacteraemia and bacteriuria separately, PLT transfusion was still associated with each infection outcome (adjusted OR for bacteraemia 3.30, 95% CI 2.30 − 4.74, *p* \<0.01 and adjusted OR for bacteriuria 2.01, 95% CI 1.44--2.83, *p* \<0.01). There was a dose effect in the association between PLT transfusion and infection (adjusted OR for one PLT unit 1.62, 95% CI 1.11--2.35, *p* = 0.01; adjusted OR for two PLT units 3.48, 95% CI 2.60--4.68, *p* \< 0.01). Figure [1](#Fig1){ref-type="fig"} shows the survival time analysis for infection in patients with and without PLT and Fig. [2](#Fig2){ref-type="fig"} shows the survival time analysis for bacteraemia in patients with and without PLT.Table 6Independent risk factors for infection in the Cox modelVariables^a^Adjusted hazard ratio95% Confidence interval*P* valuePLT transfusion1.851.41-2.41\<0.01Gender0.430.35-0.52\<0.01APACHE III score1.001.00-1.010.20RBC^b^1.020.79-1.330.86FFP^b^0.870.66-1.140.32Cryoprecipitate^b^1.010.74-1.400.94Invasive mechanical ventilation0.770.57-1.060.11RRT1.331.03-1.710.03^a^Other confounders include centre, year and admission diagnosis. ^b^Only blood products transfused prior to infection are considered in the analysis. *RBC* red blood cells, *FFP* fresh frozen plasma, *RRT* renal replacement therapy, *PLT* platelets, *APACHE* Acute Physiology And Chronic Health Evaluation Fig. 1Kaplan-Meier estimates of infection in all patients over 40 days after ICU admission (*p* \< 0.01 by the log-rank test) Fig. 2Kaplan-Meier estimates of bloodstream infections in all patients over 40 days after ICU admission (*p* \< 0.01 by the log-rank test) )

Discussion {#Sec12}
==========

In this large observational study, PLT transfusion was associated with ICU-acquired infection. This association remained after adjustment for important confounders, including administration of other blood products prior to PLT administration and when considering all blood components as time varying covariates. PLT transfusion was still an independent risk factor for infection when considering separately bacteraemia and bacteriuria as an outcome.

Comparison with the available literature {#Sec13}
----------------------------------------

It has been suggested that there is an association between infections and PLT administration in trauma and post-cardiac-surgery settings \[[@CR5], [@CR6], [@CR18]\]. In a post hoc analysis of data from six randomised trials, Spiess et al. found that PLT transfusion was associated with an increased risk of critical adverse events including infection \[[@CR5]\]. Nonetheless, the study conducted by Spiess et al. was performed before the widespread use of leukoreduction of blood components and its statistical analysis did not adjust for all other blood components administered.

More recently, Bilgin et al. reported on 1085 cardiac surgery patients in whom the risk of death due to post-surgical infection was independently associated with PLT transfusion \[[@CR6]\]. However, the criteria to define infection were not objective, with infection diagnosis based on the "physician's opinion". In both studies, microbiology data were not provided. In contrast, there was no association between PLT transfusion and infection or morbidity in other large cohorts of patients who had undergone cardiac surgery \[[@CR19]--[@CR21]\]. Despite these conflicting results, the plausibility of this association is supported by reports showing the independent role of PLT in transfusion-related immunomodulation in animals \[[@CR10]\].

Strengths and limitations {#Sec14}
-------------------------

To our knowledge, this is the largest available study investigating the association between PLT transfusion and hospital-acquired infections in critically ill patients. Its heterogeneous population and its multi-centre design support the generalizability of our findings. The consistent results with different modelling approaches and the consideration of transfusion of blood components as time-varying to overcome survival bias is another strength that has not been used commonly in similar studies on this topic. The use of prospectively maintained databases of infectious outcomes and microbiology criteria to define infection also reduced bias, which may be introduced if relying on subjective definitions of infection by clinicians.

Nonetheless, our study has some limitations. Its retrospective design did not allow adjustment for relevant but missing data. Although we did perform propensity covariate adjustment to account for the probability of receiving a PLT transfusion, estimation of the propensity score could only be based on the available data. Infections that could not be reliably identified in our data could not be included in the analysis, such as ventilator-associated pneumonia or abdominal infections. Bacteraemia sources were not recorded, making it impossible to classify bacteraemia according to the infection source. There was no information on whether the patient was on antibiotics at the time the microbiology samples were obtained. Such information would have been useful to better understand the relatively low rate of infection in our population. Data were not available on blood components given prior to ICU admission, and infections occurring after ICU discharge. Finally, although we adjusted for important factors known to influence the risk of infection, we cannot exclude the possibility that the observed associations were confounded by unmeasured factors.

Implications of study findings {#Sec15}
------------------------------

Our results suggest an association between PLT transfusion and adverse clinical outcomes, and emphasise the importance of avoiding unnecessary transfusions. Avoiding unnecessary transfusion should be a priority and may decrease hospital-acquired infection \[[@CR3]\].

Conclusion {#Sec16}
==========

In conclusion, we found an independent association between PLT transfusion and the risk of hospital-acquired infections in critically ill patients. This association should be taken into account when transfusing PLT in critically ill patients. Further research to understand this association and to better determine the benefit of PLT in this population is warranted.

Appendix {#Sec17}
========

Propensity covariate adjustment {#Sec18}
-------------------------------

Table 7Independent risk factors for infection in a multivariate analysis including propensity covariate adjustmentVariables^a^Adjusted odds ratio95% Confidence interval*P* valuePLT2.451.89-3.18\<0.01Gender0.400.32-0.49\<0.01APACHE III score1.001.01-1.010.01RBC transfusion^b^1.391.08-1.780.01FFP transfusion^b^0.690.46-1.020.06Cryoprecipitate^b^0.700.39-1.280.25Invasive mechanical ventilation2.892.07-5.46\<0.01RRT3.902.79-5.46\<0.01Propensity covariate^c^3.461.15-10.380.03^a^Other confounders include centre, year and admission diagnosis. ^b^Only blood products transfused prior to platelets (PLT) transfusion are considered in the analysis. ^c^Propensity covariate predicted by gender, site, diagnosis, immune disease, immunosuppressed, chronic liver disease, year, red blood cells (RBC) transfusion, fresh frozen plasma (FFP) transfusion, cryoprecipitate transfusion, invasive mechanical ventilation, renal replacement therapy (RRT), age, leukaemia/myeloma, metastases, hepatic failure, insulin-dependent diabetes. *APACHE* Acute Physiology And Chronic Health Evaluation

APACHE

:   Acute Physiology And Chronic Health Evaluation

CI

:   Confidence interval

Cryo

:   Cryoprecipitate

FFP

:   Fresh frozen plasma

HR

:   Hazard ratio

ICU

:   Intensive care unit

IQR

:   Interquartile range

MV

:   Mechanical ventilation

OR

:   Odds ratio

PLT

:   Platelets

RBC

:   Red blood cells

RRT

:   Renal replacement therapy
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